Further Weakness as Enanta Pharmaceuticals (NASDAQ:ENTA) Drops 15% This Week, Taking Five-year Losses to 84%
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shareholders should be happy to see the share price up 20% in the last quarter. But will that repair the damage for the weary investors who have owned thi
Simply Wall StApr 18 06:37 ET
Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
PDF Version WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 17, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indica
Enanta PharmaceuticalApr 17 00:00 ET
Inventiva Phase 2 Study for MASH Drug Meets Primary Endpoint
Seeking AlphaMar 18 17:45 ET
Madrigal Climbs Amid Hopes for New NASH Drug; B. Riley Upgrades
Seeking AlphaMar 15 08:19 ET
Madrigal and Liver Drug Developers Fall Ahead of FDA Decision on NASH Therapy
Seeking AlphaMar 14 10:42 ET
Liver Drug Developers Outperform as U.S. Awaits First NASH Drug
Seeking AlphaMar 13 13:29 ET
Enanta Pharmaceuticals Shareholders Affirm Management Direction
TipRanksMar 12 16:13 ET
Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference
PDF Version WATERTOWN, Mass.--(BUSINESS WIRE)--Mar. 6, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indica
Enanta PharmaceuticalMar 6 00:00 ET
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shares have continued their recent momentum with a 27% gain in the last month alone.
Simply Wall StMar 5 05:01 ET
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported And Analysts Have Been Cutting Their Estimates
As you might know, Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) last week released its latest quarterly, and things did not turn out so great for shareholders. Unfortunately, Enanta Pharmaceuticals
Simply Wall StFeb 12 06:12 ET
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating
Enanta Pharmaceuticals (ENTA) has an average rating of outperform and price targets ranging from $11 to $35, according to analysts polled by Capital IQ.
MT NewswiresFeb 9 09:00 ET
Oppenheimer Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)
TipRanksFeb 9 07:58 ET
Maintaining Hold on Enanta Pharmaceuticals Amid Near-Term Challenges and Pipeline Potential
TipRanksFeb 9 00:51 ET
Enanta Pharmaceuticals Is Maintained at Underweight by JP Morgan
Enanta Pharmaceuticals Is Maintained at Underweight by JP Morgan
Dow JonesFeb 8 16:54 ET
Express News | JP Morgan Maintains Underweight on Enanta Pharma, Lowers Price Target to $11
Moomoo 24/7Feb 8 16:43 ET
Enanta Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/08/2024 -11% JP Morgan $12 → $11 Maintains Underweight 11/22/2023 69.9% Oppenheimer $25 → $21 Maintains
BenzingaFeb 8 16:42 ET
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Arrowhead Pharmaceuticals (ARWR)
TipRanksFeb 8 08:10 ET
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Enanta Pharmaceuticals (ENTA) and Steris (STE)
TipRanksFeb 8 00:30 ET
Earnings Call Summary | Enanta Pharmaceuticals(ENTA.US) Q1 2024 Earnings Conference
The following is a summary of the Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript:Financial Performance:Enanta reported a total revenue of $18 million for Q1 2024, down from $23.6
moomoo AIFeb 7 23:19 ET · Conference Call
Recap: Enanta Pharma Q1 Earnings
Enanta Pharma (NASDAQ:ENTA) reported its Q1 earnings results on Wednesday, February 7, 2024 at 04:01 PM.Here's what investors need to know about the announcement.EarningsEnanta Pharma missed estimated
BenzingaFeb 7 16:15 ET
No Data
No Data